Texas Digestive Disease Consultants

Fort Worth, Texas 76104

1 studies enrolling now · 5 studies all time

What they study most

Compensated Cirrhosis, Crohn Disease (CD), Non Alcoholic Steatohepatitis (NASH), Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Primary Biliary Cholangitis, Ulcerative Colitis (UC)

Studies at this site

• INSIGHT-IBD Pragmatic Study — Starting soon
• A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) — Running, not enrolling
• Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment — Stopped early
• Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis — Completed
• ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA) — Completed